| Enhanced safety and efficacy of protease-regulated CAR-T cell receptors L Labanieh, RG Majzner, D Klysz, E Sotillo, CJ Fisher, JG Vilches-Moure, ... Cell 185 (10), 1745-1763. e22, 2022 | 105 | 2022 |
| Structure and functional binding epitope of V-domain Ig suppressor of T cell activation N Mehta, S Maddineni, II Mathews, RAP Sperberg, PS Huang, ... Cell reports 28 (10), 2509-2516. e5, 2019 | 72 | 2019 |
| IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions W Kelton, N Mehta, W Charab, J Lee, C Lee, T Kojima, TH Kang, ... Chemistry & biology 21 (12), 1603-1609, 2014 | 70 | 2014 |
| An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA N Mehta, S Maddineni, RL Kelly, RB Lee, SA Hunter, JL Silberstein, ... Scientific reports 10 (1), 15171, 2020 | 38 | 2020 |
| An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy SA Hunter, BJ McIntosh, Y Shi, RAP Sperberg, C Funatogawa, ... Communications Biology 4 (1), 452, 2021 | 22 | 2021 |
| Antibodies with engineered IgG Fc domains G Georgiou, W Kelton, N Mehta US Patent 9,890,216, 2018 | 6 | 2018 |
| Engineering anti-AML antibodies for improved NK cell ADCC V Senyukov, W Kelton, N Mehta, G Georgiou, D Lee Blood 120 (21), 3629, 2012 | 2 | 2012 |
| A neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC AC Boroughs, I Scarfo, N Attanasio, T Gardner, JB Smith, J McDevitt, ... Cancer Research 83 (7_Supplement), 4088-4088, 2023 | | 2023 |
| High-throughput arrayed screening of logic-gated CARs enables the selection of candidates for ccRCC with optimal potency and fidelity traits N Mehta, J Thomas, E Yashin, A Fua, J Li, J Chen, L Lim, J Chua, ... Cancer Research 83 (7_Supplement), 1783-1783, 2023 | | 2023 |
| Vista-binding antibodies and uses thereof RL Kelly, N Mehta US Patent App. 17/438,407, 2022 | | 2022 |
| Novel Notch-Like Receptors with Increased Potency and Fidelity for Synthetic Gene Circuits in Primary Human T Cells N Mehta, J Pierce, S Kyriazopoulou-Panagiotopoulou, R Sit, ... MOLECULAR THERAPY 30 (4), 348-349, 2022 | | 2022 |
| Abstract PO-048: VISTA immune-checkpoint blunts radiotherapy induced anti-tumor immune response DK Nambiar, N Mehta, S Maddineni, H Cao, V Viswanathan, ... Clinical Cancer Research 27 (8_Supplement), PO-048-PO-048, 2021 | | 2021 |
| Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development NK Mehta Stanford University, 2020 | | 2020 |
| Beyond Antibodies: Engineered Protein Scaffolds for Therapeutic Development NK Mehta, JR Cochran Protein Therapeutics 1, 161-188, 2017 | | 2017 |
| Engineering an antagonist of the urokinase receptor to inhibit cancer growth and metastasis G Cherf, N Mehta, J Kintzing, J Cochran ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 253, 2017 | | 2017 |
| Engineered microgels L Suggs, S Makhija, N Mehta, D Min, A Sharma US Patent App. 14/859,731, 2016 | | 2016 |
| Antibodies with engineered igg fc domains G Georgiou, W Kelton, N MEHTA | | 2014 |
| Introducing new effector function to IgG via protein engineering of an IgA-IgG hybrid antibody N Mehta | | 2013 |
